Change over period: —
NSE · JAGSNPHARM
JAGSON PHAR
-14.6% from the 52-week high · +29.3% above the low
Jagsonpal Pharmaceuticals Ltd. is a pharmaceutical company, which engages in the development and manufacture of intermediate drugs and pharmaceutical formulations. The company is headquartered in New Delhi, Delhi and currently employs 940 full-time employees. The firm is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its formulation products include Divatrone, Maintane 500 injection, Maintane 250 injection, Maintane Tablet, Indocap capsules, Metadec 50 injection, Metadec 25 injection, EndoReg Tablet, LycoRed softgels, LycoRed syrup, Doxypal DR-L Capsule, Yuliprist Tablet, COLLA-2 Tablet, Cystelia M, and DeeReg Tablet, among others. Its OTC products include Ringcuter Cream, Skin Lumia Soap-Antibacterial, and Skin Lumia Soap-Neem Tulsi. Its Naari products include Endoreg, Yuliprist, Verena, Kyrah, Krampoff, Endonorm EV2, Divagest SR 300, Divagest SR 200, Cystelia 35, Fibristone 25, and Cystelia-M. Its other products include Lycored Softgels, Lycored Syrup, JP Tone Syrup, and Doxypal DR-L. The Company’s therapy areas include gynecology, orthopedics, and others.
The short version. Promoter holding was 68.81% in Sep 2026, up 1.00 points over 8 quarters.
1 · The price
How has the stock traded?
JAGSON PHAR trades 14.6% below its 52-week high and 29.3% above its 52-week low.
2 · The business
Is it growing?
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | |
|---|---|
| Revenue | 96 |
| Net profit | 12 |
| Net margin % | 12.8 |
| EPS (₹) | 1.86 |
4 · The owners
Who holds it, and are they adding?
Up 1.0 pts over 8 quarters.
Up 0.04 pts over 8 quarters.
Up 1.65 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 67.81 | 67.78 | 67.65 | 67.54 | 67.39 | 67.89 | 69.05 | 68.81 | +1.0 |
| FII | 2.1 | 2.1 | 2.18 | 2.12 | 2.12 | 2.44 | 2.3 | 2.14 | +0.04 |
| DII | 0 | 0 | 0.05 | 0.09 | 0.15 | 0.22 | 0.62 | 1.65 | +1.65 |
| Public | 30.08 | 30.11 | 30.12 | 30.25 | 30.34 | 29.45 | 28.03 | 27.4 | -2.68 |
Mutual fund holdings · Oct 2026
2 schemes hold this stock
2 the month before.
- Motilal Oswal BSE Healthcare ETF0.02% of NAV
- Bandhan BSE Healthcare Index Fund0.02% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for JAGSON PHAR are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about JAGSON PHAR
What is the JAGSON PHAR share price?
JAGSON PHAR (JAGSNPHARM) last closed at ₹210.39, up 1.02% on the day. Its 52-week range is ₹161.07 to ₹243.97.
What is the market cap of JAGSON PHAR ?
JAGSON PHAR has a market capitalisation of about ₹1,379 crore. Its price-to-earnings ratio is 31.2.
How are JAGSON PHAR 's latest results?
Promoter holding was 68.81% in Sep 2026, up 1.00 points over 8 quarters.
Who owns JAGSON PHAR ?
As of Sep 2026, shareholding was: Promoter 68.81%, FII 2.14%, DII 1.65%, Public 27.4%.
How many mutual funds hold JAGSON PHAR ?
2 mutual fund schemes held JAGSON PHAR in October 2026. That compares with 2 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 12 Sep 2025 · Final Dividend - Rs. 2.5
- 08 Jan 2025 · Stock Split From Rs.5/- to Rs.2/-
- 06 Sep 2024 · Final Dividend - Rs. 5
- 21 Aug 2023 · Dividend - Rs. 5
- 29 Oct 2021 · Interim Dividend - Rs. 4
- 22 Sep 2021 · Dividend - Rs. 1
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.